These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 33862558)

  • 1. PARP inhibitors in head and neck cancer: Molecular mechanisms, preclinical and clinical data.
    Moutafi M; Economopoulou P; Rimm D; Psyrri A
    Oral Oncol; 2021 Jun; 117():105292. PubMed ID: 33862558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual disruption of DNA repair and telomere maintenance for the treatment of head and neck cancer.
    Lajud SA; Nagda DA; Yamashita T; Zheng J; Tanaka N; Abuzeid WM; Civantos A; Bezpalko O; O'Malley BW; Li D
    Clin Cancer Res; 2014 Dec; 20(24):6465-78. PubMed ID: 25324139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Linifanib (ABT-869), enhances cytotoxicity with poly (ADP-ribose) polymerase inhibitor, veliparib (ABT-888), in head and neck carcinoma cells.
    Hsu HW; de Necochea-Campion R; Williams V; Duerksen-Hughes PJ; Simental AA; Ferris RL; Chen CS; Mirshahidi S
    Oral Oncol; 2014 Jul; 50(7):662-9. PubMed ID: 24735547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA double strand break repair defect and sensitivity to poly ADP-ribose polymerase (PARP) inhibition in human papillomavirus 16-positive head and neck squamous cell carcinoma.
    Weaver AN; Cooper TS; Rodriguez M; Trummell HQ; Bonner JA; Rosenthal EL; Yang ES
    Oncotarget; 2015 Sep; 6(29):26995-7007. PubMed ID: 26336991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies.
    Padella A; Ghelli Luserna Di Rorà A; Marconi G; Ghetti M; Martinelli G; Simonetti G
    J Hematol Oncol; 2022 Jan; 15(1):10. PubMed ID: 35065680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer.
    Moutafi M; Koliou GA; Papaxoinis G; Economopoulou P; Kotsantis I; Gkotzamanidou M; Anastasiou M; Pectasides D; Kyrodimos E; Delides A; Giotakis E; Papadimitriou NG; Panayiotides IG; Perisanidis C; Fernandez AI; Xirou V; Poulios C; Gagari E; Yaghoobi V; Gavrielatou N; Shafi S; Aung TN; Kougioumtzopoulou A; Kouloulias V; Palialexis K; Gkolfinopoulos S; Strati A; Lianidou E; Fountzilas G; Rimm DL; Foukas PG; Psyrri A
    Cancer Res Commun; 2023 Aug; 3(8):1514-1523. PubMed ID: 37575280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined EGFR1 and PARP1 Inhibition Enhances the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Models.
    Frederick BA; Gupta R; Atilano-Roque A; Su TT; Raben D
    Radiat Res; 2020 Nov; 194(5):519-531. PubMed ID: 32936912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing poly (ADP-ribose) polymerase inhibition through combined epigenetic and immunotherapy.
    Prasanna T; Wu F; Khanna KK; Yip D; Malik L; Dahlstrom JE; Rao S
    Cancer Sci; 2018 Nov; 109(11):3383-3392. PubMed ID: 30230653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The DNA damage response network in the treatment of head and neck squamous cell carcinoma.
    Psyrri A; Gkotzamanidou M; Papaxoinis G; Krikoni L; Economopoulou P; Kotsantis I; Anastasiou M; Souliotis VL
    ESMO Open; 2021 Apr; 6(2):100075. PubMed ID: 33714009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A high homologous recombination deficiency score is associated with poor survival and a non-inflamed tumor microenvironment in head and neck squamous cell carcinoma patients.
    Chen Y; Zheng X; Lin J; Gao X; Xiong J; Liu J; Fei Z; Chen C
    Oral Oncol; 2022 May; 128():105860. PubMed ID: 35428026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA Damage Repair and the Emerging Role of Poly(ADP-ribose) Polymerase Inhibition in Cancer Therapeutics.
    Rabenau K; Hofstatter E
    Clin Ther; 2016 Jul; 38(7):1577-88. PubMed ID: 27368114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cetuximab augments cytotoxicity with poly (adp-ribose) polymerase inhibition in head and neck cancer.
    Nowsheen S; Bonner JA; Lobuglio AF; Trummell H; Whitley AC; Dobelbower MC; Yang ES
    PLoS One; 2011; 6(8):e24148. PubMed ID: 21912620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Base excision repair defects invoke hypersensitivity to PARP inhibition.
    Horton JK; Stefanick DF; Prasad R; Gassman NR; Kedar PS; Wilson SH
    Mol Cancer Res; 2014 Aug; 12(8):1128-39. PubMed ID: 24770870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metformin reverses PARP inhibitors-induced epithelial-mesenchymal transition and PD-L1 upregulation in triple-negative breast cancer.
    Han Y; Li CW; Hsu JM; Hsu JL; Chan LC; Tan X; He GJ
    Am J Cancer Res; 2019; 9(4):800-815. PubMed ID: 31106005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy.
    Javle M; Curtin NJ
    Ther Adv Med Oncol; 2011 Nov; 3(6):257-67. PubMed ID: 22084640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The poly(ADP-Ribose) polymerase inhibitor ABT-888 reduces radiation-induced nuclear EGFR and augments head and neck tumor response to radiotherapy.
    Nowsheen S; Bonner JA; Yang ES
    Radiother Oncol; 2011 Jun; 99(3):331-8. PubMed ID: 21719137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel therapeutic combinations with PARP inhibitors for small cell lung cancer: A bench-to-bedside review.
    Xiong J; Barayan R; Louie AV; Lok BH
    Semin Cancer Biol; 2022 Nov; 86(Pt 2):521-542. PubMed ID: 35917883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PARP Inhibitors in Clinical Use Induce Genomic Instability in Normal Human Cells.
    Ito S; Murphy CG; Doubrovina E; Jasin M; Moynahan ME
    PLoS One; 2016; 11(7):e0159341. PubMed ID: 27428646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors.
    Peyraud F; Italiano A
    Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32526888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies.
    Rimar KJ; Tran PT; Matulewicz RS; Hussain M; Meeks JJ
    Cancer; 2017 Jun; 123(11):1912-1924. PubMed ID: 28323334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.